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ABSTRACT
The increased survival in malignant cutaneous melanoma (melanoma) is probably due to early 
diagnosis combined with improved treatment most recently. National health campaigns and screening 
programs for melanoma detection were started in Sweden several decades ago. We want to assess the 
influence of tumor characteristics, based on the TNM classification, and of second primary cancers on 
overall survival in melanoma. We used the Swedish Cancer Registry to assess all-cause survival in 
melanoma from 2003 to 2015. Hazard ratios (HRs) were estimated using multivariable Cox regression 
models. A total of 19,773 melanoma patients were diagnosed with TNM data. Survival showed a 
strong improving trend over time (P-trend<0.001). T1a was the most common classification (48.0% of 
all) while higher T class associated systematically with worse survival (P-trend<0.001). For distant 
metastases the HR was 3.17, accounting for 0.9% of the patients. Any types of second primary 
cancers, other than melanoma, were associated with an HR of 2.00, accounted for 6.7% of all cases. 
Even if melanoma survival in Sweden ranks among the best national rates, the large percentage of 
patients advanced tumors (T3b, T4a and T4b, 17%) and 21% of deaths with T1a call for improved 
preventive and follow-up strategies. 
Key words: TNM, tumor characteristics, metastasis, prognosis, survival.
Significance
The positive trend in melanoma survival has stalled in USA and Sweden. Here the influence of tumor 
characteristics on overall survival was assessed based on the TNM classification. The three highest T 
classes (T3b, T4a and T4b) accounting for 16.8% of all melanoma showed respective hazard ratios as 
3.71, 4.37 and 5.90 against T1a. The large percentage of melanoma with advanced tumors may 
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INTRODUCTION
Five-year survivals in white American patients with malignant cutaneous melanoma (subsequently 
‘melanoma’) have improved from about 80% in 1975 to 90% by 2012 while there has been an 
increase in incidence (Jemal et al., 2017). A similar positive trend has also been observed in Europe 
(Crocetti et al., 2015; Lyth et al., 2015). Survival is critically dependent on whether the tumor is 
localized (96%), or spread to distant sites (41%), according to a US study, but even for thick localized 
tumors survival is decreased (Lo et al., 2018; Pollack et al., 2011). The reasons for the positive 
development are not entirely clear but tumor thickness is strongly related to survival and the overall 
tumor thickness has generally decreased in USA and parts of Europe (Lyth et al., 2015; Robsahm et 
al., 2018; Shaikh et al., 2016). However, there are indications that the positive trend in survival has 
stalled in USA and Sweden, suggesting the importance of novel strategies for early diagnosis (Jemal 
et al., 2017; Lyth et al., 2015). It is possible that therapy has also contributed to favorable prognosis 
even though the successes in targeted therapies including immunotherapy in metastatic melanoma 
may not yet be evident at the population level (Eggermont et al., 2014; Hartman and Lin, 2019; 
Schadendorf et al., 2018). Favorable trends in survival will inevitably result in an increased likelihood 
of second primary cancers (SPCs). According to a recent Swedish study, SPCs, including second 
melanoma, were diagnosed in 13.3% of melanoma patients and these were often found to be the 
causes of death (Chattopadhyay et al., 2019). 
In the present study we want to characterize the influence of tumor thickness and ulceration on 
survival in melanoma patients. In multivariable analyses we want to compare survival depending on 
tumor characteristics, locoregional and distant metastases, including patients with second melanoma 
or other SPC. 
METHODS
This is a national cohort study based on Swedish Cancer Registry where data for first melanoma and 
any subsequent cancers were obtained recording cancers according to the International Classification 
of Diseases 7th revision (ICD-7, code 200 for cutaneous melanoma) and later revisions. The clinical 
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started at that time. A number of 19,838 (69.1%) patients with TNM classification were identified 
among 28,716 melanoma patients from 2003. After excluding 65 melanoma patients with unspecified 
tumor thickness (Tx), the total number of patients in the study was 19,773. Melanoma staging 
followed principally that of the American Joint Committee on Cancer (AJCC) sixth edition, published 
in 2001 (Balch et al., 2001). Towards the end of the study period the AJCC seventh edition was taken 
to use with the basic difference for the present study that an index for mitotic rate was introduced as 
an additional distinction between T1a and T1b (Balch et al., 2009). The exact timing of the switch to 
the seventh edition throughout the country is not known but in the national care program for 
melanoma, published in May 2013, the seventh edition was recommended as basis of classification 
(Nationellt vårdprogram malignt melanom – kortversion ISBN: 978-91-86929-09-1 Maj 2013). 
Nevertheless, considering the relatively good survival in melanoma overall we can assume that 
practically all melanoma deaths in the present study with follow up until the end of year 2015 were in 
patients who were classified according to the sixth edition.
Using the sixth edition, tumor thickness (T1 ≤1mm, T2 1-2mm, T3 3-4mm and T4>4mm) together 
with ulceration status (a, no ulceration and b, ulceration) was classified into eight groups including 
T1a, T1b, T2a, T2b, T3a, T3b, T4a and T4b. We considered locoregional (N) and distant (M) 
metastases, denoted by N+ (N1, N2, N3) or M+ (M1, M2); Nx and Mx denote undefined metastatic 
status. We followed newly diagnosed patients with melanoma from 1st January 2003 until 31st 
December 2015 for diagnosis of any of the 35 different SPCs including second melanomas. The 
follow-up for survival was terminated at emigration, death, or 31st December 2015, whichever 
occurred earliest. 
Hazard ratios (HRs) for overall survival were estimated with Cox regression, adjusted for gender, age 
at diagnosis (≤50, 51-60, 61-70, 71-80, 81-90 and ≥91years old), year of diagnosis (≤2005, 2006-2010 
and 2011-2015), tumor  thickness, ulceration and histology (superficial spreading, nodular, lentigo 
maligna and other melanomas) of the first melanoma, locoregional and distant metastasis and 
diagnoses of SPC. Hazards for patients with different baseline tumor thickness/ulceration were 
compared to patients with T1 and without ulceration (T1a, reference population). In the Cox model, 
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bias (Anderson et al., 1983). Trend test was performed by considering groups of variable of interest as 
continuous variables. Kaplan-Meier survival curves stratified by tumor thickness and ulceration were 
generated for patient with and without SPC. 
All the statistical tests were two sided and P < 0.05 was considered significant. Analyses were done 
with R version 3.4, SAS version 9.4 and Stata version 15.1. ‘coxph’ function of ‘survival’ package in 
R was used to perform Cox regression with time-dependent variable.
The study was approved 6 February 2013 by the Ethical Review Board of Lund University (Dnr 
2012/795), without requirement for informed consent. Through advertisements in the major 
newspapers people could chose to opt out before the research database were constructed. The project 
database is located at Center for Primary Health Care in Malmö, Sweden.
RESULTS
A total of 19,773 patients were diagnosed with first melanoma with TNM staging from 2003 to 2015. 
Gender, age at diagnosis and year of diagnosis, TNM classification, histology and SPC diagnosis of 
patients are shown in Table 1.  Most of the patients were diagnosed with T1a (48.0%), followed by 
T2a (16.3%). Because of the clinical TNM classification, undefined (Nx, Mx) cases were common 
and confirmed locoregional (2.5%) or distant metastases (0.9%) were rare. Superficial spreading 
melanoma accounted for more than half of the patients (58.8%). During follow-up time, 2030 (11.3%) 
patients developed SPCs, including 706 (3.6%) second melanomas. 
Table 2 displays how demographic and clinical factors affect survival of melanoma patients in 
multivariable Cox analyses. Patients with older age at diagnosis had poor survival; for age over 91 
years, the HR increased up to 15.98 (95%CI: 13.08-19.51). Female patients were observed with better 
prognosis compared to males (0.69, 0.64-0.74). HRs showed a periodic decline in risk from the 
reference rate of 1.00 in 2003-2005 to 0.73 in 2006-2010 and 0.51 in 2011-2015 (P-trend <0.001); for 
the patients diagnosed in 2011-2015, the HR (0.51, 0.45-0.59) was approximately 50% of that for 
those diagnosed before 2006. Compared to patients diagnosed with T1a, the HR for patients with T1b 
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T4b. It is noteworthy that T1a accounted for 20.9% of all deaths, and the three T classes (T3b, T4a 
and T4b) combined account for another 48.1% with respective high HRs of 3.71, 4.37 and 5.90. 
The trend test for tumor thickness and ulceration showed high significance (P-trend <0.001, Table 2). 
Patients with locoregional (2.24, 1.82-2.75) and distant metastases (3.17, 2.40-4.19) had poorer 
prognosis than those without. Note that for many patients metastatic status was undefined (Nx or Mx) 
and the HRs were low (1.29 and 0.92, respectively), indicating that most of these patients had no 
metastases. Nodular melanoma (NM, 1.14, 1.03-1.26), and lentigo melanoma (1.20, 1.02-1.41) 
showed worse survival than superficial spreading melanoma (SSM); the other histology types 
additionally included undefined histologies (1.10, 1.00-1.22). The increased HR for nodular 
melanoma was only modest, in spite of the number of cases, which equaled that of superficial 
spreading melanoma; the reason was the high age of patients with nodular melanoma.   Patients with 
second melanoma had poorer survival (1.48, 1.23-1.78) compared to patients with only first 
melanoma. The survival was worse for patients with other SPC (2.00, 1.75-2.30) which accounted for 
6.7% of all cases. The trend test for SPC diagnosis was highly significant (P-trend <0.001).
Kaplan-Meier survival probability stratified by tumor T class and ulceration in patients without SPC 
diagnosis is displayed in Figure 1. Consistent with Table 2, the worse survival (25% in 12 years) was 
observed for patients with thick tumors and ulceration. Patients with T1a had a survival of close to 
90% after the 12-year follow-up time, and somewhat better than that of patients with T1b and T2a. 
Survival curves for T2b and T3a clustered close to each other as did those for T3b and T4a. Kaplan-
Meier survival plots were also generated for patients with SPC diagnosis (Figure 2). The differences 
in survival probability between various tumor T classes in patients with SPC were not as apparent as 
that in patients without. For the same tumor T class and ulceration, survival probabilities in patients 
with SPC were generally lower than those without.  
DISCUSSION
In this nationwide cohort study including 19,773 melanoma patients with and TNM data, we found 
that old age at diagnosis and male sex were associated with decreased survival. Survival showed a 
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three highest T classes (T3b, T4a and T4b), totally accounting for 16.8% of all patients, and showed 
the respective HRs were as high as 3.71, 4.37 and 5.90. For distant metastases the HR was 3.17, 
accounting for 0.9% of the patients. Second primary cancers other than melanoma were associated 
with decreased survival, accounted for 6.7% of all cases.  
Surgery is the main treatment modality for melanoma and a study published in 2016 based on the 
Stockholm Melanoma Register showed that 98.9% of all patients underwent surgery at baseline 
(Rockberg et al., 2016). However the percentage was stage dependent and for stage IV (metastatic) 
patients it was only 52.2% but such patients with distal metastases accounted for only 1.3% of all 
patients. Targeted therapy with BRAF and MEK inhibitors and immunotherapies with checkpoint 
inhibitors have been recent highlights in the fight against melanoma death in metastatic disease 
(Eggermont et al., 2014; Schadendorf et al., 2018). The approval by the European Medicines Agency 
for BRAF was in 2012 and for the combo BRAF+MEK it was 2014. The first checkpoint inhibitor 
ipilimumab was approved in Europe in 2011 but the use has been limited because of toxicity and 
limited effectiveness (Rozeman et al., 2018). It was not until 2015 when nivolumab and 
pembrolizumab were approved that the use of checkpoint inhibitors started to increase. The periodic 
HRs in Table 2 showed a time-dependent decline in risk from a reference rate of 1.00 in 2003-2005 to 
0.73 in 2006-2010 and 0.51 in 2011-2015 (P for trend <0.001). BRAF inhibitors may have 
contributed to the decline in the last period but probably other factors play the main role (Helgadottir 
et al., 2018). Earlier diagnosis of thinner lesions contributes to improved survival but there is concern 
that screening campaigns may lead to overdiagnosis which, however, in the case of melanoma is a 
minor issue (Breitbart et al., 2012; Crocetti et al., 2015; Lyth et al., 2015; Shaikh et al., 2016; Weyers, 
2018). 
The present results emphasize the role of tumor characteristics in influencing survival. In the 
multivariable analysis, three T classes (T3b, T4a and T4b), combined accounting for 16.8% of all 
patients were associated with worse survival. The HR for patients with distant metastases, 0.9% of all 
patients, was 3.17 in this study. The latter percentage is an underestimate because of many patients 
presented with an undefined metastasis status at diagnosis. However, two Swedish studies based on ad 









This article is protected by copyright. All rights reserved
(Rockberg et al., 2016; Utjes et al., 2017). Of note, as we wanted to see the effects from SPC 
diagnosis, the present data included all deaths while some survival literature covers melanoma-
specific survival. For example, a recent Norwegian study on melanoma-specific survival reported a 
HR of 16.82 for distant metastases and 9.68 for T4 class; the follow-up time was short from 2008 to 
2015 which additionally emphasizes the role of metastases at diagnosis (Robsahm et al., 2018). While 
that study and a few others have considered survival in patients with second melanoma, our study is 
probably the only one so far considering other SPCs in the multivariable models (Utjes et al., 2017). 
SPCs other than melanoma may be highly fatal and they should be included on any cancer-related 
survival studies (Chattopadhyay et al., 2019).   
In a European comparison on melanoma survival Sweden ranked the third after Northern Ireland and 
Switzerland (Crocetti et al., 2015). Yet, the present results call for novel approaches in melanoma 
prevention. In Sweden national multi-level melanoma prevention campaigns were started already in 
the late 1980s; these included education for physicians, nurses and the general population (Ringborg 
et al., 1991). Different screening approaches were tested at the population level (Tornberg et al., 
1996). The results suggest that such programs do not reach all walks of life; low level of education 
was associated with reduced melanoma-specific survival, which was at least partially attributed to 
advanced stages at diagnosis (Eriksson et al., 2013). The present finding that 10.9% of melanomas 
present with T4 class, i.e., thicker than 4 mm and 2/3 of them with ulceration is another witness to a 
limited population penetrance of the Swedish health education, in spite of all efforts. One cost 
effective screening option would be to link skin examination to the national mammographic screening 
program which in Sweden is attended by 80% of the eligible women (Norfjord Van Zyl et al., 2018). 
Unfortunately, the 20% non-attendees are probably also a problem population for melanoma. As 
mortality in melanoma is lower for women than for men, alerting men would be particularly 
important. Skin examination should be part of regular (opportunistic) health examinations but again 
non-attendees are a likely risk group.   
An important point is that in spite of the above discussion on deleterious survival consequences of 
higher T classes, the bottom line was that 21% of melanoma deaths were in patient with T1a staging, 
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diagnosed patients, for which recommendations are given in the national care programs for melanoma 
(Wikstrom et al., 2018). In the program from year 2013, referred to in Methods, the recommendation 
for low-risk patients (T1a) was a single dermatological follow-up visit after 4 to 6 weeks following 
surgery. This recommendation is essentially repeated in the program from year 2017.  Probably the 
patient was reassured that the risk is low and in so believing he may overlook signs of recurrent 
disease. 
The strengths of the present study include nation-wide coverage of histologically verified melanomas 
and of deaths. This is the first study which included SPCs in the multivariable survival analysis, and 
in doing all-cause mortality was recorded instead of melanoma-specific mortality. The weaknesses are 
the relatively short follow-up which was due to the late collection of TNM data by the Cancer 
Registry. We only included the patients with TNM classification, which may introduce selection bias. 
Even though the nation-wide enactment of TNM classification could have been less than 
homogeneous, there is hardly any evidence of drastic change in treatment modalities during the 
initiation period. Tumor thickness is crucial and the T1 class is unable to gauge further details and 
these have been added into the later editions of the classification system. The start of the TNM 
coverage of the classification is random unlikely to be sensitive to selection bias. 
In conclusion, the multivariable survival data showed that the three highest T classes, which 
accounted for 16.8% of all patients, were associated with worst survival. In spite of various 
melanoma-directed health campaigns many patients presented with delayed diagnoses. Mortality 
reducing melanoma prevention programs would require some novel approaches to reach the least 
health-conscious segments of the population. Better utilization of primary care clinics, of more 
widespread use of in vivo diagnostic technologies, and of new available smartphone “apps” may be 
helpful. For example, there are applications that can be used to indicate which moles might need 
treatment, but the challenge is how to get people-at-risk to use them (Marek et al., 2018b; Marek et 
al., 2018a). Finally, as 21% of deaths were found among T1a patients, a clinical follow-up plan 
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The data that support the findings of this study are available from Lund University but restrictions 
apply to the availability of these data, which were used under license for the current study, and so are 
not publicly available.
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Figure 1 Survival probability stratified with tumor  thickness and ulceration after diagnosis of first 
melanoma in patients without SPC diagnosis. SPC, second primary cancer, a, no ulceration, b, with 
ulceration. 
Figure 2 Survival probability stratified with tumor  thickness and ulceration after diagnosis of first 
melanoma in patients with SPC diagnosis. SPC, second primary cancer, a, no ulceration, b, with 
ulceration.
REFERENCES
Anderson, J. R., Cain, K. C., and Gelber, R. D. (1983). Analysis of survival by tumor response. J Clin 
Oncol 1, 710-9.
Balch, C. M., Buzaid, A. C., Soong, S. J., Atkins, M. B., Cascinelli, N., Coit, D. G., Fleming, I. D., 
Gershenwald, J. E., Houghton, A., Jr., Kirkwood, J. M., et al. (2001). Final version of the 
American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 
19, 3635-48.
Balch, C. M., Gershenwald, J. E., Soong, S. J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, 
A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009). Final version of 2009 AJCC 
melanoma staging and classification. J Clin Oncol 27, 6199-206.
Breitbart, E. W., Waldmann, A., Nolte, S., Capellaro, M., Greinert, R., Volkmer, B., and Katalinic, A. 
(2012). Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 66, 201-
11.
Chattopadhyay, S., Hemminki , A., Försti, A., Sundquist, K., Sundquist, J., and Hemmiinki, K. 
(2019). Familial risks and mortality in second primary cancers in melanoma. JNCI Cancer 
Spectrum 2, pky068.
Crocetti, E., Mallone, S., Robsahm, T. E., Gavin, A., Agius, D., Ardanaz, E., Lopez, M. C., Innos, K., 
Minicozzi, P., Borgognoni, L., et al. (2015). Survival of patients with skin melanoma in 









This article is protected by copyright. All rights reserved
Eggermont, A. M., Spatz, A., and Robert, C. (2014). Cutaneous melanoma. Lancet 383, 816-27.
Eriksson, H., Lyth, J., Mansson-Brahme, E., Frohm-Nilsson, M., Ingvar, C., Lindholm, C., Naredi, P., 
Stierner, U., Wagenius, G., Carstensen, J., et al. (2013). Low level of education is associated 
with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a 
nationwide population-based study in Sweden. Eur J Cancer 49, 2705-16.
Hartman, R. I., and Lin, J. Y. (2019). Cutaneous Melanoma-A Review in Detection, Staging, and 
Management. Hematology/oncology clinics of North America 33, 25-38.
Helgadottir, H., Rocha Trocoli Drakensjo, I., and Girnita, A. (2018). Personalized Medicine in 
Malignant Melanoma: Towards Patient Tailored Treatment. Frontiers in oncology 8, 202.
Jemal, A., Ward, E. M., Johnson, C. J., Cronin, K. A., Ma, J., Ryerson, B., Mariotto, A., Lake, A. J., 
Wilson, R., Sherman, R. L., et al. (2017). Annual Report to the Nation on the Status of Cancer, 
1975-2014, Featuring Survival. J Natl Cancer Inst 109.
Lo, S. N., Scolyer, R. A., and Thompson, J. F. (2018). Long-Term Survival of Patients with Thin (T1) 
Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8 mm Separates Higher-Risk and 
Lower-Risk Tumors. Ann Surg Oncol 25, 894-902.
Lyth, J., Eriksson, H., Hansson, J., Ingvar, C., Jansson, M., Lapins, J., Mansson-Brahme, E., Naredi, 
P., Stierner, U., Ullenhag, G., et al. (2015). Trends in cutaneous malignant melanoma in 
Sweden 1997-2011: thinner tumours and improved survival among men. Br J Dermatol 172, 
700-6.
Marek, A. J., Chu, E. Y., Ming, M. E., Khan, Z. A., and Kovarik, C. L. (2018a). Impact of a 
smartphone application on skin self-examination rates in patients who are new to total body 
photography: A randomized controlled trial. J Am Acad Dermatol 79, 564-567.
Marek, A. J., Chu, E. Y., Ming, M. E., Khan, Z. A., and Kovarik, C. L. (2018b). Piloting the Use of 
Smartphones, Reminders, and Accountability Partners to Promote Skin Self-Examinations in 
Patients with Total Body Photography: A Randomized Controlled Trial. American journal of 
clinical dermatology 19, 779-785.
Norfjord Van Zyl, M., Akhavan, S., Tillgren, P., and Asp, M. (2018). Experiences and perceptions 










This article is protected by copyright. All rights reserved
county in Sweden. International journal of qualitative studies on health and well-being 13, 
1521256.
Pollack, L. A., Li, J., Berkowitz, Z., Weir, H. K., Wu, X. C., Ajani, U. A., Ekwueme, D. U., Li, C., 
and Pollack, B. P. (2011). Melanoma survival in the United States, 1992 to 2005. J Am Acad 
Dermatol 65, S78-86.
Ringborg, U., Lagerlof, B., Broberg, M., Mansson-Brahme, E., Platz, A., and Thorn, M. (1991). Early 
detection and prevention of cutaneous malignant melanoma: emphasis on Swedish activities. 
Medical oncology and tumor pharmacotherapy 8, 183-7.
Robsahm, T. E., Helsing, P., Nilssen, Y., Vos, L., Rizvi, S. M. H., Akslen, L. A., and Veierod, M. B. 
(2018). High mortality due to cutaneous melanoma in Norway: a study of prognostic factors in 
a nationwide cancer registry. Clinical epidemiology 10, 537-548.
Rockberg, J., Amelio, J. M., Taylor, A., Jorgensen, L., Ragnhammar, P., and Hansson, J. (2016). 
Epidemiology of cutaneous melanoma in Sweden-Stage-specific survival and rate of 
recurrence. Int J Cancer 139, 2722-2729.
Rozeman, E. A., Dekker, T. J. A., Haanen, J., and Blank, C. U. (2018). Advanced Melanoma: Current 
Treatment Options, Biomarkers, and Future Perspectives. American journal of clinical 
dermatology 19, 303-317.
Schadendorf, D., Van Akkooi, A. C. J., Berking, C., Griewank, K. G., Gutzmer, R., Hauschild, A., 
Stang, A., Roesch, A., and Ugurel, S. (2018). Melanoma. Lancet 392, 971-984.
Shaikh, W. R., Dusza, S. W., Weinstock, M. A., Oliveria, S. A., Geller, A. C., and Halpern, A. C. 
(2016). Melanoma Thickness and Survival Trends in the United States, 1989 to 2009. J Natl 
Cancer Inst 108.
Tornberg, S., Mansson-Brahme, E., Linden, D., Ringborg, U., Krakau, I., Karnell, R., Landegren, J., 
Brandberg, Y., and Hakulinen, T. (1996). Screening for cutaneous malignant melanoma: a 
feasibility study. J Med Screen 3, 211-5.
Utjes, D., Lyth, J., Lapins, J., and Eriksson, H. (2017). Reduced disease-specific survival following a 
diagnosis of multiple primary cutaneous malignant melanomas-a nationwide, population-










Weyers, W. (2018). Screening for malignant melanoma-a critical assessment in historical perspective. 
Dermatology practical & conceptual 8, 89-103.
Wikstrom, J. D., Lundeberg, L., Frohm-Nilsson, M., and Girnita, A. (2018). Differences in cutaneous 
melanoma treatment and patient satisfaction. PLoS One 13, e0205517.














Male  9711 49.1Gender Female 10062 50.9
≤2005  2409 12.2
2006-2010 6812 34.5Calendar year of  diagnosis
2011-2015 10912 55.2







Tumor staging (T) 
T4b 1439 7.3
N0 14084 71.2
N+ 488 2.5Locoregional metastasis (N)
Nx 5201 26.3
M0 13690 69.2





Other and missing 3969 20.1
Without SPC  17743 89.7
Second melanoma 706 3.6SPC diagnosis
Other SPC 1324 6.7
N+ includes N1, N2 and N3; M+ includes M1 and M2
SPC, second primary cancer
SSM, superficial spreading melanoma, NM, nodular melanoma, LMM, lentigo maligna melanoma, other melanomas 
include acral lentiginous melanoma, desmoplastic melanoma and some others.
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Table 2 Multivariable Cox proportional regression model for survival in melanoma patients 
Covariate No. at risk No. of death HR 95%CI P-value
Age at diagnosis ≤50 (ref) 5542 237 1.00 - -
51-60 3840 278 1.42 1.20 1.70 <0.001
61-70 5142 518 2.04 1.75 2.39 <0.001
71-80 4351 860 3.71 3.19 4.32 <0.001
81-90 2497 1022 8.46 7.26 9.85 <0.001
≥91 430 267 15.98 13.08 19.51 <0.001
P-Trend <0.001
Gender Male (ref) 10909 1888 1.00 - -
Female 10893 1294 0.69 0.64 0.74 <0.001
Calendar year ≤2005 (ref) 2403 722 1.00 - -
2006-2010 7691 1585 0.73 0.65 0.81 <0.001
2011-2015 11708 875 0.51 0.45 0.59 <0.001
P-Trend <0.001
Tumor staging T1a (ref) 10384 664 1.00 - -
T1b 1710 127 1.44 1.20 1.73 <0.001
T2a 3574 349 1.46 1.28 1.66 <0.001
T2b 865 142 2.38 1.98 2.86 <0.001
T3a 1635 369 2.71 2.36 3.11 <0.001
T3b 1284 425 3.71 3.23 4.27 <0.001
T4a 780 313 4.37 3.72 5.13 <0.001






1700 1.00 - -
Nx 5839 1225 1.29 1.11 1.50 <0.001
N+ 531 257 2.24 1.82 2.75 <0.001
Distant metastasis M0 (ref) 14977 1661 1.00 - -
Mx 6639 1395 0.92 0.79 1.07 0.28
M+ 186 126 3.17 2.40 4.19 <0.001
Histology SSM (ref) 12816 1168 1.00 - -
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LMM 1195 202 1.20 1.02 1.40 0.03
Other 4347 682 1.10 1.00 1.22 0.05
Diagnosis of SPC Without SPC  17743 2644 1.00 - -
Second melanoma 706 133 1.48 1.23 1.78 <0.001
Other SPC 1323 405 2.00 1.75 2.30 <0.001
P-Trend <0.001
N+ includes N1, N2 and N3; M+ includes M1 and M2
HR, hazard ratio, CI, confidence interval, SPC, second primary cancer
SSM, superficial spreading melanoma, NM, nodular melanoma, LMM, lentigo maligna melanoma, other melanomas 
include acral lentiginous melanoma, desmoplastic melanoma and some others. 
A
cc
ep
te
d 
A
rt
ic
le
pcmr_12868_f1.tif
This	article	is	protected	by	copyright.	All	rights	reserved
A
cc
ep
te
d 
A
rt
ic
le
pcmr_12868_f2.tif
This	article	is	protected	by	copyright.	All	rights	reserved
A
cc
ep
te
d 
A
rt
ic
le
